ClinicalTrials.gg
RecruitingNCT06763081PGx-SImBAUpdated Sep 8, 2025

Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation

An observational study in Behavioral Activation, Major Depressive Disorder and Anxiety Disorders, sponsored by University of Manitoba. Recruiting at 2 sites in Canada. Open to participants aged 6 Years to 24 Years. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by University of Manitoba · Observational

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
160
Ages
6 Years to 24 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 312 studies in Depressive Disorder, Major with a site in Canada — 66 open to participants now, 82 under way, 12 of them phase 3. Depressive Disorder, Major · Canada.

Planned enrollment
10th of 27
160 · median 120
Started
2025
with 18 others
Observational
28 of 312
9 open now
Primary completion
2028-12
later than 72 of 81 live
Registered
281st of 312
by date

Among the 312 studies in Depressive Disorder, Major with a site in Canada, this one is the 10th largest by planned enrollment of the 27 observational ones that give a count, is one of 19 that started in 2025, is one of 28 observational ones, reaches primary completion later than 72 of the 81 other live ones, and was the 281st registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

66 of the 312 studies in Depressive Disorder, Major with a site in Canada are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 6 Years to 24 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 312 studies in Depressive Disorder, Major with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this study is to identify and validate a panel of genetic markers associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioural activation in children and youth with major depressive disorder (MDD), anxiety disorders, or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.

Read the detailed description

Background and Rationale: Major depressive disorder (MDD), anxiety disorders, and obsessive-compulsive disorder (OCD) are among the most common mental health disorders in children and youth. Antidepressants such as selective serotonin reuptake inhibitors (SSRIs) are the most frequently prescribed medications for this population. Although SSRIs are generally effective and well-tolerated, some children and youth suffer from burdensome adverse effects. One such adverse effect is "behavioural activation", which is characterized by a rapid onset of hyperactivity, impulsivity, irritability, or insomnia that can lead to consequences such as violence and suicidal ideation. Collectively, this can impose a major burden on families as well as a substantial economic cost to society. Unfortunately, there are no clinically useful markers available to assist clinicians in predicting which children and youth will experience behavioural activation as a result of SSRI treatment. Given that the use of these medicines in Canada is steadily increasing, solutions to curb the incidence of SSRI-induced behavioural activation are needed. The proposed study provides one such solution by identifying genetic markers associated with this adverse event.

Objectives: The proposed study aims to identify and validate a panel of genetic markers associated with SSRI-induced behavioural activation in children and youth with MDD, anxiety disorders, or OCD that could ultimately be used clinically to reduce the incidence of this adverse event and improve health outcomes.

Methods: Children and youth (aged 24 years or younger) who developed (cases) or did not develop (controls) behavioural activation after taking an SSRI will be matched on age, sex, ethnicity, diagnosis, and the SSRI prescribed. One hundred participants (50 cases, 50 controls) will be recruited. Participants will be recruited from the Child and Adolescent Mental Health Program at the Health Sciences Centre, the Children's Hospital of Winnipeg, pediatric community clinics, and clinics currently participating in the Manitoba Primary Care Research Network. Saliva samples will be collected from these children and youth. DNA will be extracted and genotyped using a comprehensive pharmacogenomic array. Pharmacogenomic profiles of the two groups will be compared to identify a panel of genetic variants associated with SSRI-induced behavioural activation. Finally, the panel will be replicated using an independent cohort of children and youth with SSRI-induced behavioural activation from the University of Calgary.

Expected Outcomes: The study not only provides the opportunity to advance knowledge in a grossly understudied area but also directly addresses a clinical need that, if fulfilled, could drastically reduce the incidence of a potentially severe adverse event associated with the care of children and youth with MDD, anxiety disorders, and OCD. The study will provide an initial and crucial step for achieving this anticipated impact by enabling the discovery of pharmacogenomic markers that could then be taken forward and tested in prospective clinical trials and ultimately integrated into clinical practice.

03

Conditions studied

  • Behavioral Activation
  • Major Depressive Disorder
  • Anxiety Disorders
  • Antidepressant Drug Adverse Reaction
  • Obsessive Compulsive Disorder (OCD)
  • Major Depression

Keywords

  • SSRI
  • Depression
  • OCD
  • Anxiety
  • Antidepressants
  • Children
  • Adolescents
  • Mood Disorders
  • Drug-induced Adverse Events
  • Youth
  • Mental Illness
  • Mental disorders
  • Drug-Related Side Effects and Adverse Reactions
  • Selective Serotonin Reuptake Inhibitor
  • Disinhibition
04

Who can participate

Ages eligible
6 Years to 24 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

SSRI-treated children and adolescents diagnosed with major depression, anxiety disorders, or OCD, aged 6 to 24 years, recruited from the Child and Adolescent Mental Health Program at the Health Sciences Centre, Manitoba Adolescent Treatment Centre, the Children's Hospital of Winnipeg, pediatric community clinics, and family health clinics in Manitoba, Canada.

Eligibility criteria

Inclusion criteria: Participants will be eligible for participation if all of the following are true.

  • Resident of Manitoba
  • Age, 6 - 24 years
  • Diagnosis of major depressive disorder (MDD), anxiety disorder, or obsessive-compulsive disorder (OCD)
  • Current or past history of selective serotonin reuptake inhibitor (SSRI), e.g., Citalopram [Celexa], Escitalopram [Cipralex], Fluoxetine [Prozac], Fluvoxamine [Luvox], Sertraline [Zoloft], Paroxetine [Paxil/Plaxil CR]) therapy
  • [Cases Only] Have experienced behavioural side effects after taking an SSRI that resolved after reducing the dose or discontinuation of the drug
  • [Controls Only] Did not experience any side effects after taking an SSRI for eight (8) continuous weeks

Exclusion criteria: Participants will be excluded from participation if any of the following are true.

  • Inability of parent/legal guardian/mature minors to give
  • Inability of the child (6 - 13 years) to give informed assent
  • Unwillingness of the child to provide a saliva sample for genetic analysis
  • Current, past, or suspected diagnosis of attention deficit hyperactivity disorder (combined or hyperactive type), oppositional defiant disorder, conduct disorder, bipolar disorder, psychotic disorder, pervasive developmental disorder
  • History of liver or bone marrow (hematopoietic cell) transplant.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
160 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • OtherNot applicable- observational study

    It's an observational study. Participants are not assigned an intervention as part of the study.

06

What researchers measure

Primary outcomes

  1. Pharmacogenomics variants associated with SSRI-induced behavioural activation

    DNA will be extracted from all participants at baseline using standard procedures and genotyped using the Infinium global diversity array (GDA) with an enhanced PGx array (Illumina Canada, Vancouver, Canada). Pharmacogenomic profiles (1,933,117 markers) of participants who developed (cases) or did not develop (controls) behavioural activation after taking an SSRI will be compared to identify a panel of genetic variants associated with SSRI-induced behavioural activation.

    Time frame: Baseline, study-enrollment

  2. Assessment of behavioural activation

    To characterize and systematically assess SSRI-induced activation syndrome, all participants at baseline will be asked to complete a modified version of the Treatment-Emergent Activation and Suicidality Assessment Profile (TEASAP) scale with the help of their parents/guardians (informants).

    Time frame: Baseline, at study enrollment

Secondary outcomes

  1. Effect of genetic variation on SSRI-Induced adverse effects

    A self-report instrument, The Antidepressant Side-Effect Checklist (ASEC) will be used to compare the common adverse drug reactions to SSRI antidepressants in all participants.

    Time frame: Baseline, at study enrollment

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2028, 45 months after the start.

Of 121 non-industry observational studies under Depressive Disorder, Major, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 73. This study's planned 45 months is close to that.

Counting every sponsor, half of 150 studies reached it within 38 months; a quarter within 21 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2024
First posted
Jan 8, 2025
StartActual
Mar 1, 2025
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2030
Last update
Sep 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06763081
Collaborators
Health Sciences Centre Foundation, Manitoba, Children's Hospital Research Institute of Manitoba, University of Calgary
Responsible party
Abdullah Al Maruf (Assistant Professor, University of Manitoba) — Principal investigator
First posted
Jan 8, 2025
Start date
Mar 1, 2025
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Sep 8, 2025

Study contacts

Abdullah A Maruf, BPharm, MPharm, PhD
Contact
abdullah.maruf@umanitoba.ca
204-318-2575

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion